Predict your next investment

Pyramid Biosciences company logo
HEALTHCARE | Drug Discovery

See what CB Insights has to offer

Founded Year



Series B | Alive

Total Raised


Last Raised

$28M | 1 yr ago

About Pyramid Biosciences

Pyramid Biosciences is a drug discovery company focused on novel small molecule therapeutics targeting dermatology, oncology and neuropsychiatric disorders involving dysregulation of the Trk signaling pathway.

Pyramid Biosciences Headquarter Location

330 Bear Hill Road Suite 302

Waltham, Massachusetts, 02451,

United States


Latest Pyramid Biosciences News

Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology

May 20, 2021

05/20/2021 | 08:03am EDT Message : PBI-100 is a highly-selective tropomyosin receptor kinase (TRK) inhibitor Psoriasis affects more than 120 million people worldwide, nearly eight million in US Pyramid Biosciences, Inc., a clinical-stage, biotechnology company developing novel precision therapies, announced that it has commenced a Phase 1 clinical study for its therapeutic candidate PBI-100, a first-in-class topical treatment targeting mild to moderate psoriasis in patients. Psoriasis is an immune-mediated skin disease1, where an overactive immune system causes a rapid increase in keratinocyte production that can lead to raised, flaking skin lesions. People living with psoriasis report symptoms such as itching, burning and stinging.2 “Dosing our first patient is an important milestone for Pyramid Biosciences, physicians, and most importantly, patients suffering from psoriasis and other inflammatory skin disorders,” said Kollol Pal, PhD, co-founder, and CEO of Pyramid Biosciences. “We expect that PBI-100 will offer benefit for many patients currently suffering without an effective treatment option.” Inflammatory skin diseases are one of the leading causes of global disease burden. Psoriasis affects approximately 125 million people globally3, and topical treatments remain one of the mainstays of current medical treatment. In the United States, psoriasis affects nearly eight million people.4 PBI-100, a highly-selective TRK kinase inhibitor, provides a novel mechanism of action for the treatment of psoriasis and targets both the psoriatic lesions as well as related symptoms including itch. Pyramid Biosciences plans to conduct further clinical testing of PBI-100 for use in additional indications. The Phase 1 study is recruiting healthy volunteers to assess the safety and tolerability of multiple dose levels of PBI-100. The single arm, blinded, randomized, controlled study is based in the U.S. and will enroll 25 people in its first round. Additional information can be found at (Reference: NCT04882631 ). __________________________

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pyramid Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pyramid Biosciences is included in 3 Expert Collections, including Biopharmaceuticals.



5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.



2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Pyramid Biosciences Patents

Pyramid Biosciences has filed 1 patent.

The 3 most popular patent topics include:

  • Cannabinoids
  • Designer drugs
  • Indoles
patents chart

Application Date

Grant Date


Related Topics



Designer drugs, Pyrrolidines, Metal halides, Cannabinoids, Indoles


Application Date


Grant Date


Related Topics

Designer drugs, Pyrrolidines, Metal halides, Cannabinoids, Indoles



CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.